Mark T. Fleming
Mark T. Fleming publishes mostly in Pulmonary and Respiratory Medicine, Oncology and Surgery, on topics such as Prostate Cancer Treatment and Research, Radiopharmaceutical Chemistry and Applications and Bladder and Urothelial Cancer Treatments.
- World rank
- #167,823 of 7,710,434 ranked researchers
- Rank in United States
- #62,876 of 1,627,098
- Works
- 213
- Citations
- 16k
- Citations per work
- 75.9
What does Mark T. Fleming research?
Mark T. Fleming's work is mostly in Medicine (58%), Biochemistry, Genetics and Molecular Biology (6%), Health Professions (4%).
Their six largest subfields, inside their fields and domains; the grey slice is everything else they publish. The interactive view splits every one of their works down to single topics.
The fields and subfields, with their numbers
- Health Sciences13161.7%
- Medicine12357.6%
- Health Professions94.1%
- Everything else6832.1%
- Life Sciences136.2%
- 1Pulmonary and Respiratory Medicine24% of their works
- 2Oncology12% of their works
- 3Surgery12% of their works
- 4Radiology, Nuclear Medicine and Imaging9% of their works
- 5Molecular Biology6% of their works
- 6Radiological and Ultrasound Technology4% of their works
Research topics
- Prostate Cancer Treatment and Research
- Radiopharmaceutical Chemistry and Applications
- Bladder and Urothelial Cancer Treatments
- Cancer Immunotherapy and Biomarkers
- Prostate Cancer Diagnosis and Treatment
- Occupational Health and Safety Research
- Cancer Treatment and Pharmacology
- Urinary and Genital Oncology Studies
Which keywords describe Mark T. Fleming's research?
The keywords of their largest research topics: Immunotherapy, Prostate Cancer, Androgen Receptor, Genomic Profiling, PET Imaging, Radiopharmaceuticals, Bladder Cancer and Urothelial Carcinoma.
- Urachal Carcinoma
- Primary Urethral Carcinoma
- Safety Culture
- Screening
- PD-1 and PD-L1
- Urothelial Carcinoma
- Radiopharmaceuticals
- Genomic Profiling
- Prostate Cancer
- Immunotherapy
- Androgen Receptor
- PET Imaging
- Bladder Cancer
- Immune Checkpoint Blockade
- Radiation Therapy
- Occupational Safety
- Chemotherapy-Induced Peripheral Neuropathy
- Taxanes
Size is their works in the topics tagged with each word, from their 8 largest topics. Each links to the topic it comes from most. The words come from the keyword list OpenAlex gives each topic, not from the text of the papers, so a word can appear that none of the papers uses.
All 18 words, with their numbers
- Immunotherapy1152 topics
- Prostate Cancer952 topics
- Androgen Receptor721 topic
- Genomic Profiling721 topic
- PET Imaging441 topic
- Radiopharmaceuticals441 topic
- Bladder Cancer431 topic
- Urothelial Carcinoma431 topic
- Immune Checkpoint Blockade281 topic
- PD-1 and PD-L1281 topic
- Radiation Therapy231 topic
- Screening231 topic
- Occupational Safety211 topic
- Safety Culture211 topic
- Chemotherapy-Induced Peripheral Neuropathy201 topic
- Primary Urethral Carcinoma201 topic
- Taxanes201 topic
- Urachal Carcinoma201 topic
Where does Mark T. Fleming work?
Mark T. Fleming's main affiliation in the publication record is Virginia Oncology Associates, United States.
How many publications and citations does Mark T. Fleming have?
OpenAlex counts 213 works and 16,164 citations for Mark T. Fleming, an h-index of 44, ranking #167,823 of 7,710,434 researchers worldwide on the quality score.
Ranked on field-normalised citation excellence (50%), output (30%) and citations (20%). Counts come from OpenAlex author records, which occasionally merge different people who share a name or split one person into several.
Papers, co-authors, who cited this work and researchers on the nearest topics have tabs of their own, above. Is this your page? Claim it with your ORCID iD, or request a correction or removal.
Discussion
Ask a question or share a note about Mark T. Fleming. Keep it to the research: no personal attacks, advertising or links. Any reader can report a post, which collapses it for everyone until it is opened.